About Dr. Qin Shukui
Dr. Qin Shukui (秦叔逵) is one of China's most eminent medical oncologists, serving as Chief Physician, Professor, and Director of the National Cancer Center / National Clinical Research Center for Cancer at the PLA Cancer Center (People's Liberation Army Cancer Center) at Jinling Hospital in Nanjing, with extensive clinical and academic ties to Shanghai's leading oncology institutions. With over four decades of clinical excellence and pioneering research in systemic cancer therapy, Dr. Qin has established himself as a defining authority in hepatocellular carcinoma (HCC), gastrointestinal tumors, and the design of landmark clinical trials that have shaped global oncology practice.
Dr. Qin's clinical program is among the highest-volume and most complex in China, managing thousands of advanced cancer patients annually, including many referred after exhausting treatment options elsewhere. His leadership in international multi-center trials has directly influenced global drug approvals and treatment guidelines for liver and gastrointestinal cancers.
Medical Expertise & Core Specializations
Dr. Qin's clinical mastery spans the full spectrum of systemic oncology, with particular distinction in four critical areas:
1. Hepatocellular Carcinoma (HCC) — Liver Cancer (肝细胞癌)
Dr. Qin is recognized as China's foremost authority on systemic treatment of liver cancer. His expertise includes:
- Targeted Therapy: Sorafenib, lenvatinib, regorafenib, cabozantinib — optimizing sequencing and dosing for individual patients
- Immunotherapy & Combinations: Atezolizumab + bevacizumab, sintilimab + IBI305, and emerging PD-1/PD-L1 combinations
- Conversion Therapy: Systemic treatment to downstage unresectable HCC toward surgical resection or ablation
- Biomarker-Driven Selection: Identifying patients most likely to respond to specific regimens based on molecular profiling
Conditions treated include: Early, intermediate, and advanced HCC; hepatitis B/C-related liver cancer; recurrent HCC post-resection or ablation; HCC with portal vein tumor thrombus (PVTT); and fibrolamellar HCC.
2. Gastrointestinal Tumors (消化道肿瘤)
Dr. Qin leads one of China's most comprehensive GI oncology programs, addressing:
- Gastric Cancer: Perioperative chemotherapy, HER2-targeted therapy (trastuzumab), and immunotherapy combinations
- Colorectal Cancer: FOLFOX/FOLFIRI regimens, anti-VEGF/EGFR biologics, and MSI-H immunotherapy
- Pancreatic Cancer: FOLFIRINOX, gemcitabine-based regimens, and novel investigational agents
- Biliary Tract Cancer: Gemcitabine + cisplatin, FGFR/IDH-targeted therapies, and immunotherapy
Special expertise in: Metastatic GI cancers, conversion therapy for borderline resectable disease, and rare GI tumors including GIST and neuroendocrine tumors.
3. Clinical Trial Leadership & Drug Development (临床试验)
Dr. Qin is China's most prolific principal investigator for oncology clinical trials, having led or co-led over 100 pivotal studies:
- Landmark HCC Trials: Principal investigator for REFLECT (lenvatinib vs sorafenib), HIMALAYA, CARES-310, and multiple China-specific registration trials
- GI Cancer Trials: Key investigator for gastric, colorectal, and biliary tract cancer studies that led to NMPA and FDA approvals
- Early-Phase Studies: First-in-human and Phase I/II trials of novel targeted agents and immunotherapy combinations
- Real-World Evidence: National registry studies capturing outcomes across China's diverse patient population
4. Multidisciplinary Cancer Management (多学科综合治疗)
Dr. Qin champions an integrated, team-based approach to complex cancer care:
- MDT Coordination: Leading multidisciplinary tumor boards integrating surgery, interventional radiology, radiation oncology, and pathology
- Personalized Treatment Planning: Molecular tumor profiling (NGS, liquid biopsy) to guide individualized therapy
- Supportive & Palliative Care: Integrating symptom management, nutrition, and quality-of-life optimization throughout treatment
- Second Opinion Consultations: Reviewing complex cases from across China and internationally
Academic Achievements & National Leadership
Prestigious Academic Honors & Leadership Roles
- Chairman, Chinese Society of Clinical Oncology (CSCO) (中国临床肿瘤学会理事长): Leading China's premier oncology professional society, representing over 30,000 oncologists and setting national treatment guidelines
- Chairman, CSCO Hepatobiliary Cancer Expert Committee (CSCO肝癌专家委员会主任委员): Authoring and updating China's national HCC treatment guidelines
- Member, ASCO, ESMO, AASLD: Active participant in the world's leading oncology and hepatology societies
- Editorial Board Member: Multiple international journals including Journal of Clinical Oncology, Hepatology, and leading Chinese oncology publications
- National Key Opinion Leader (KOL): Recognized by China's National Medical Products Administration (NMPA) as a leading expert in oncology drug evaluation
Research & Publications
Dr. Qin has authored over 400 peer-reviewed publications in prestigious journals including Journal of Clinical Oncology, The Lancet Oncology, JAMA Oncology, Hepatology, and leading Chinese medical journals. His research focuses on:
- Systemic therapy optimization for HCC and GI cancers
- Immunotherapy mechanisms and resistance in solid tumors
- Biomarker discovery for treatment selection
- Real-world outcomes and health economics in oncology
- Novel drug combinations and sequencing strategies
Education & Training
As a professor and doctoral supervisor, Dr. Qin has trained over 150 oncology residents, fellows, and graduate students. Many of his trainees now lead oncology departments across China. He is a frequent keynote speaker at CSCO, ASCO, ESMO, and APASL annual meetings.
Clinical Volume & Excellence
- Annual Patient Volume: Thousands of new and follow-up cancer patients managed per year, with a high proportion of advanced and refractory cases
- Trial Portfolio: Over 100 clinical trials conducted, with results published in top-tier international journals and presented at major global conferences
- Guideline Authorship: Primary author or co-author of China's national HCC, gastric cancer, and colorectal cancer treatment guidelines
- International Collaboration: Active partnerships with Memorial Sloan Kettering, MD Anderson, and leading European cancer centers
- Drug Approvals: Clinical trial leadership directly contributed to NMPA approval of multiple oncology agents now standard of care in China
Why International Patients Choose Dr. Qin Shukui
1. Unmatched Expertise & Experience
Dr. Qin's four decades of experience, national guideline leadership, and role as principal investigator in landmark global trials place him at the absolute pinnacle of medical oncology in China. Few oncologists worldwide possess his combination of clinical volume, research impact, and institutional authority.
2. Cost-Effective World-Class Care
Advanced cancer treatment — including immunotherapy, targeted therapy, and clinical trial access — is available at 60-80% lower cost in China compared to the US, UK, or Australia, without compromising quality or access to cutting-edge agents.
3. Access to Cutting-Edge Clinical Trials
Dr. Qin's active trial portfolio means eligible patients may access investigational agents not yet available elsewhere, often at no cost for the study drug. This is a unique advantage for patients with refractory or rare cancers.
4. Comprehensive, Coordinated Care
From molecular profiling through systemic therapy, interventional procedures, and supportive care, patients receive seamless multidisciplinary treatment under Dr. Qin's leadership.
5. Cultural Competency for Asian Patients
Dr. Qin's deep understanding of hepatitis B-related HCC — the predominant liver cancer etiology in Asia — and GI cancers prevalent in Asian populations makes him uniquely suited to treat patients from across Asia and the Asian diaspora worldwide.
6. Advanced Facilities & Technology
China's top-tier cancer centers rival or exceed Western institutions in diagnostic technology, molecular pathology, and treatment infrastructure, while offering private rooms and attentive nursing care.
7. Proven International Track Record
Dr. Qin has successfully managed international patients and provided second-opinion consultations for complex cancer cases from across Asia, the Middle East, and beyond.
Conditions & Procedures
Liver & Biliary Cancers
- Hepatocellular carcinoma (HCC) — all stages
- Intrahepatic cholangiocarcinoma
- Gallbladder cancer
- Extrahepatic bile duct cancer
- Combined hepatocellular-cholangiocarcinoma (cHCC-CCA)
Gastrointestinal Cancers
- Gastric and gastroesophageal junction (GEJ) adenocarcinoma
- Colorectal cancer (colon and rectal)
- Pancreatic ductal adenocarcinoma
- Esophageal cancer
- Gastrointestinal stromal tumor (GIST)
- Neuroendocrine tumors (NET/NEC)
Other Solid Tumors
- Hepatoblastoma (pediatric liver cancer)
- Rare abdominal and retroperitoneal tumors
- Cancer of unknown primary (CUP) with GI/hepatic features
Specialized Services
- Second opinion consultations for complex oncology cases
- Molecular tumor board review (NGS, liquid biopsy interpretation)
- Clinical trial eligibility assessment
- Refractory/relapsed cancer management
The Patient Journey: From Consultation to Recovery
Step 1: Initial Consultation (Remote or In-Person)
International patients typically begin with a remote consultation. Our medical concierge team collects medical records, pathology reports, imaging studies (CT, MRI, PET), and molecular profiling results, which are reviewed by Dr. Qin's team. Within 5-7 business days, patients receive:
- Detailed treatment plan and recommended regimen
- Clinical trial eligibility assessment
- Comprehensive cost estimate
- Expected outcomes and potential risks
Step 2: Pre-Arrival Planning
Once treatment is scheduled, our team coordinates:
- Visa invitation letters for medical travel
- Flight and accommodation recommendations
- Airport pickup and local transportation
- Pre-treatment testing requirements
- Medical interpretation services
Step 3: Arrival & Pre-Treatment Evaluation
Upon arrival (typically 2-3 days before treatment initiation):
- In-person consultation with Dr. Qin
- Comprehensive medical evaluation and baseline testing
- Molecular profiling if not yet completed
- Final treatment planning and consent
Step 4: Treatment & Monitoring
Systemic therapy is administered at China's premier cancer centers with:
- State-of-the-art infusion suites and monitoring
- Regular imaging and biomarker assessment
- Proactive toxicity management
- Private consultation rooms and attentive nursing care
Step 5: Response Assessment & Adaptation
After initial treatment cycles, patients undergo:
- Imaging response assessment (RECIST criteria)
- Biomarker monitoring (AFP, CEA, CA19-9 as applicable)
- Treatment modification based on response and tolerability
- MDT review for conversion to surgery or ablation if applicable
Step 6: Long-Term Follow-Up
After returning home, patients maintain contact through:
- Telemedicine video consultations
- Remote review of imaging and lab results
- Coordination with local oncologists
- Return visits for ongoing treatment cycles as needed
Patient Testimonials & Success Stories
Dr. Qin's patients consistently report renewed hope and meaningful clinical responses, even after exhausting treatment options elsewhere. International patients particularly value his meticulous case review, evidence-based approach, and genuine commitment to exploring every available option — including clinical trials — to extend survival and preserve quality of life.
Frequently Asked Questions
Does Dr. Qin speak English?
While Dr. Qin's primary language is Mandarin Chinese, our medical concierge service provides professional medical interpretation for all consultations, procedures, and follow-up appointments. Many of his team members are bilingual.
How long should I plan to stay in China for treatment?
This varies by treatment plan. Initial evaluation and first treatment cycle typically require 2-3 weeks. Ongoing cycles may be administered locally with periodic return visits every 6-12 weeks. We provide specific guidance based on your treatment plan.
What are the costs compared to Western countries?
Costs are typically 60-80% lower than comparable treatment in the US, UK, or Australia, including physician fees, drug costs, and monitoring. We provide transparent, all-inclusive quotes.
Can I access clinical trials as an international patient?
Yes, in many cases international patients are eligible for Dr. Qin's clinical trials. Our team will assess your eligibility based on your diagnosis, prior treatment history, and current health status.
What if I need ongoing treatment after returning home?
We maintain ongoing communication and can coordinate with your local oncologist. For patients on oral targeted therapies, treatment can often continue at home with periodic telemedicine check-ins with Dr. Qin's team.
Schedule Your Consultation with Dr. Qin Shukui
If you or a loved one is facing liver cancer, gastrointestinal cancer, or another complex solid tumor and are seeking a second opinion or treatment from one of China's most accomplished oncologists, our medical concierge team is here to help. We facilitate every aspect of your medical journey, including:
- Comprehensive Case Review: Detailed evaluation of your medical records, pathology, and imaging by Dr. Qin's team
- Treatment Planning: Evidence-based, personalized treatment plan with clear options and expected outcomes
- Clinical Trial Assessment: Evaluation of eligibility for cutting-edge investigational therapies
- Transparent Pricing: All-inclusive cost estimates with no hidden fees
- Travel Coordination: Visa support, flight booking assistance, and accommodation recommendations
- Hospital Coordination: Admission scheduling, pre-treatment testing, and appointment booking
- Professional Interpretation: Medical-grade translation for all appointments and procedures
- Concierge Support: Local assistance with transportation, dining, and any needs during your stay
Take the first step toward expert cancer care with Dr. Qin Shukui. Contact our medical concierge team today to schedule your consultation.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
Dr. Qin Shukui's practice represents the pinnacle of medical oncology in China, combining world-class clinical expertise, landmark research leadership, and compassionate patient care. Whether you are seeking a second opinion, access to clinical trials, or ongoing systemic therapy for liver or gastrointestinal cancer, Dr. Qin and his team offer the knowledge, experience, and dedication to help you navigate your cancer journey with confidence.
0 comentarios